UK NEQAS

Leucocyte Immunophenotyping

www.ukneqasli.co.uk





2024 - 2025 Full Programme List - EQA/PT Programmes for Flow Cytometry and Molecular Haemato-Oncology

Flow Cytometry Programmes

- CD34+ Stem Cell Enumeration
- Cerebrospinal Fluid (CSF) Immunophenotyping*
- Competency Assessment and Instrument Validation Panel for Immune Monitoring
- Haematological Malignancy Bone Marrow Aspirate Assessment*
- Immune Monitoring
- Leukaemia Immunophenotyping and Diagnostic Interpretation
- Leukaemia Diagnostic Interpretation -Institute Registration
- Leukaemia Diagnostic Interpretation -Individual Registration
- Low Level Leucocyte Enumeration
- Measurable Residual Disease for ALL by Flow Cytometry
- Measurable Residual Disease for AML by Flow Cytometry*
- Measurable Residual Disease for CLL by Flow Cytometry*
- Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry*
- Paroxysmal Nocturnal Haemoglobinuria

Molecular Haemato-Oncology Programmes

- BCR::ABL1 and AML Translocation Identification
- BCR::ABL1 Kinase Domain Variant (Mutation) Status
- BCR::ABL1 Major Quantification
- BCR::ABL1 Minor Quantification
- BRAF p.Val600Glu (V600E) Mutation Status for Hairy Cell Leukaemia
- FLT3 Mutation Status
- IG/TCR Clonality Status
- KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease
- Lymphoid Gene Panels*
- Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinaemia*
- Measurable Residual Disease for AML by Molecular Methods*
- Measurable Residual Disease for Lymphoid Neoplasms by Molecular Methods*
- Myeloid Gene Panels*
- Myeloproliferative Neoplasms Diagnostic Testing**
- NPM1 Mutation Status
- Paediatric Acute Leukaemia Translocations
- Post-Stem Cell Transplant Chimerism Monitoring

Should you wish to participate in any of the above programmes please contact:

UK NEQAS LI
Pegasus House
4th Floor Suite
463a Glossop Road
Sheffield \$10 2QD
United Kingdom

Tel: +44 (0)114 2673600 Fax: +44 (0)114 2673601

email: admin@ukneqasli.co.uk www.ukneqasli.co.uk

Please note that if your participation with UK NEQAS LI is via a non-UK distributor you should contact them directly for details of how to register.

^{**} Please note that the JAK2 p.Val617Phe Mutation Status programme has now been incorporated into the Myeloproliferative Neoplasms Diagnostic Testing programme. See website for further details.